|
STRAP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.71360000000842E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.32369999997317E-06 |
| Normal-vs-Stage2 |
4.900400E-01 |
| Normal-vs-Stage3 |
1.24010000046582E-07 |
| Normal-vs-Stage4 |
5.09190001274362E-09 |
| Stage1-vs-Stage2 |
1.061880E-02 |
| Stage1-vs-Stage3 |
1.579610E-01 |
| Stage1-vs-Stage4 |
2.411500E-02 |
| Stage2-vs-Stage3 |
1.759960E-03 |
| Stage2-vs-Stage4 |
2.021800E-04 |
| Stage3-vs-Stage4 |
2.704600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.30939999953839E-07 |
| Normal-vs-AfricanAmerican |
1.064210E-02 |
| Normal-vs-Asian |
2.97169999996516E-06 |
| Caucasian-vs-AfricanAmerican |
3.655000E-01 |
| Caucasian-vs-Asian |
7.400600E-01 |
| AfricanAmerican-vs-Asian |
2.863400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.0237000004969E-07 |
| Normal-vs-Female |
3.35719999999817E-06 |
| Male-vs-Female |
2.837800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.83330000003146E-06 |
| Normal-vs-Age(41-60Yrs) |
3.96000000013608E-07 |
| Normal-vs-Age(61-80Yrs) |
2.190200E-04 |
| Normal-vs-Age(81-100Yrs) |
1.241020E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.903800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.778600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.545200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.708600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.392800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.619000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.970200E-02 |
| Classical-VS-Follicular |
5.830200E-04 |
| Classical-VS-Other |
3.788000E-01 |
| Classical-VS-Normal |
8.06869999703252E-08 |
| Tall-VS-Follicular |
4.27710000000525E-05 |
| Tall-VS-Other |
9.431600E-01 |
| Tall-VS-Normal |
9.89089999903214E-08 |
| Follicular-VS-Other |
8.237800E-02 |
| Follicular-VS-Normal |
1.811170E-01 |
| Other-VS-Normal |
2.218800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.167360E-04 |
| Normal-vs-N1 |
1.94720017887562E-10 |
| N0-vs-N1 |
8.02340000000124E-05 |
|
|
